Amgen expects generic biologics
"Generic biologics will happen and I think we'll see them in Europe first," Amgen CEO Kevin Sharer told investors Feb. 25. The exec noted that generic biologics are "profoundly different" from conventional generic drugs, citing the need to conduct clinical trials and the larger required investment in manufacturing facilities as examples. Sharer expects that Amgen's Epogen (epoetin alfa) in Europe would be the company's first product to face generic competition; however, the CEO said, "from our patent lives here in the U.S. and for the newer products in Europe, it's a long way out for us"...
You may also be interested in...
The European Union approach to follow-on biologic products sets an "appropriate" standard, the Biotechnology Industry Organization said
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.